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Abstract. Autosomal dominant polycystic kidney disease (ADPKD) is
a common Mendelian disorder that affects approximately 1 in 1000
live births. Mutations of two genes, PKD1 and PKD2, account for the
disease in approximately 80 to 85% and 10 to 15% of the cases,
respectively. Significant interfamilial and intrafamilial renal disease
variability in ADPKD has been well documented. Locus heterogene-
ity is a major determinant for interfamilial disease variability (i.e.,
patients from PKD1-linked families have a significantly earlier onset
of ESRD compared with patients from PKD2-linked families). More
recently, two studies have suggested that allelic heterogeneity might
influence renal disease severity. The current study examined the
genotype-renal function correlation in 461 affected individuals from
71 ADPKD families with known PKD2 mutations. Fifty different
mutations were identified in these families, spanning between exon 1
and 14 of PKD2. Most (94%) of these mutations were predicted to be
inactivating. The renal outcomes of these patients, including the age
of onset of end-stage renal disease (ESRD) and chronic renal failure
(CRF; defined as creatinine clearance  50 ml/min, calculated using
the Cockroft and Gault formula), were analyzed. Of all the affected
individuals clinically assessed, 117 (25.4%) had ESRD, 47 (10.2%)
died without ESRD, 65 (14.0%) had CRF, and 232 (50.3%) had
neither CRF nor ESRD at the last follow-up. Female patients, com-
pared with male patients, had a later mean age of onset of ESRD (76.0
[95% CI, 73.8 to 78.1] versus 68.1 [95% CI, 66.0 to 70.2] yr) and CRF
(72.5 [95% CI, 70.1 to 74.9] versus 63.7 [95% CI, 61.4 to 66.0] yr).
Linear regression and renal survival analyses revealed that the loca-
tion of PKD2 mutations did not influence the age of onset of ESRD.
However, patients with splice site mutations appeared to have milder
renal disease compared with patients with other mutation types (P 
0.04 by log rank test; adjusted for the gender effect). Considerable
renal disease variability was also found among affected individuals
with the same PKD2 mutations. This variability can confound the
determination of allelic effects and supports the notion that additional
genetic and/or environmental factors may modulate the renal disease
severity in ADPKD.
Autosomal dominant polycystic kidney disease (ADPKD
[MIM 173900]) is the most common hereditary kidney disor-
der, with an incidence of approximately 1 in 1000 live births,
and accounts for approximately 5 to 8% of end-stage renal
disease (ESRD) (1,2). It is characterized by the progressive
formation and enlargement of renal cysts, typically leading to
chronic renal failure by late middle age. Other manifestations
of this disorder, such as cyst formation in non-renal organs,
cardiac valvular defects, colonic diverticulosis, and intracranial
arterial aneurysms, accompany the renal disease variably.
Linkage studies in ADPKD families have documented genetic
heterogeneity (3,4), and at least two disease genes (PKD1
[MIM 601313] on chromosome 16p13.3 and PKD2 [MIM
173910] on chromosome 4q13–23) have been identified and
characterized (5–7). A rare putative third disease gene (PKD3
[MIM 600666]) has been implicated by the identification of a
small number of families unlinked to the known gene loci
(8,9). Mutations of PKD1 and PKD2 account for the disease in
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approximately 80 to 85% and approximately 10 to 15% of
Caucasian ADPKD families, respectively (1,10). Polycystins 1
and 2, the gene products of PKD1 and PKD2, are transmem-
brane proteins that share sequence homology and are currently
thought to be part of a novel signaling pathway that regulates
intracellular calcium (11–13). Polycystin 1 is predicted to have
a receptor-like structure and may be involved in cell-cell and/or
cell-matrix interaction (12,13). In contrast, polycystin 2 shares
significant homology to and can function as a cation ion
channel subunit, with nonselective permeability (12–14). Both
proteins have been shown to interact in vitro through their
cytoplasmic region, with polycystin 1 likely functioning as a
regulator of polycystin 2 (11–14).
Disease progression of ADPKD is highly variable, with age
at onset of ESRD ranging from childhood to old age (1).
Genetic locus heterogeneity is a major determinant for inter-
familial disease variability: patients from PKD1-linked fami-
lies have a significantly earlier onset of ESRD or death when
compared with patients from PKD2-linked families (median
age: 53 [95% CI, 51.2 to 54.8] versus 69 [95% CI, 66.9 to 71.3]
yr) (15). More recently, two studies have suggested that allelic
heterogeneity in ADPKD might also influence renal disease
severity. In the first study, patients with mutations in the 3' half
of PKD1 had milder renal disease than patients with mutations
in the 5' half of the gene (16). In the second study, patients with
mutations in the 3' half of PKD2 had milder composite scores
for renal complications (i.e., presence or absence of hyperten-
sion, hematuria, renal calculi, and urinary tract infection) than
patients with mutations in the 5' half of the gene (17). How-
ever, correlation of renal function with genotype data has not
been assessed in the patients with PKD2 mutations. In the
current study, we report a pooled analysis of genotype-renal
function correlation in 461 affected individuals from 71 ADPKD
families with known PKD2 mutations.
Materials and Methods
Study Patients
The clinical and genetic data of 461 affected members from 71
ADPKD families with known germline PKD2 mutations were ana-
lyzed. The PKD2 mutations in 50 families have been previously
Figure 1. Frequency distribution of age of onset of end-stage renal disease (ESRD), death (without ESRD), and chronic renal failure (CRF)
in the study patients. Typical of type 2 ADPKD, the mode of distribution of these events occurred at a relatively late age (age range, 60 to 79
yr). However, considerable renal disease variability (age range of onset of ESRD, 40 to 88 yr) was also evident between individual patients.
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described (17–25), and the remaining mutations from 21 families are
reported here for the first time. The diagnosis of ADPKD in the
patients and at-risk individuals from each study family was estab-
lished using well-established ultrasound-based criteria (26). Any af-
fected individual with a concomitant renal disease (e.g., diabetic
nephropathy) was excluded from this study. The demographic, clini-
cal, and laboratory data (including serum creatinine and/or creatinine
clearance) were obtained from all the participants after obtaining
informed consent. All the research protocols used in the study have
been approved by the institutional review boards of all the participat-
ing centers.
Definitions of Primary Renal Outcome
Two renal disease outcomes were used in this study. End-stage
renal disease (ESRD) is defined as severe chronic renal failure with a
serum creatinine value  500 uM (or 5.7 mg/dl) or the requirement of
renal replacement therapy (chronic dialysis or renal transplantation).
Chronic renal failure (CRF) is defined as moderately severe chronic
renal failure with a calculated creatinine clearance  50 ml/min per
1.73 m2 by the formula of Cockroft and Gault (27). The study subjects
were classified as hypertensive if their systolic or diastolic BP ex-
ceeded the 95th percentile predicted for age and gender or if they
required anti-hypertensive treatment.
PKD2 Mutational Analyses
DNA isolation and mutation screening methods have been previ-
ously detailed (17–24). Single-stranded conformational polymor-
phism (SSCP), heteroduplex analysis (HA), or direct sequencing was
employed to screen all 15 exons and their flanking intronic sequences
of PKD2 (28) for PKD2 mutations in one definitively affected indi-
vidual from each study family. Whenever possible, segregation of a
specific mutation with ADPKD was tested within each family by
SSCP, HA, restriction-digestion, or allele-specific oligonucleotide
hybridization. All nonconservative missense changes identified were
also tested to determine whether they were present in at least 100
normal chromosomes. Both strands of the PCR templates containing
any variants were sequenced by the dideoxy terminator method using
an ABI 373 or 377 DNA Sequencer (Applied Biosystems). PKD2
mutations were considered 5' mutations if they were located in the
first half of the open reading frame (nucleotides 1 to 1452), or 3'
mutations if they were located in the second half of the open reading
frame (nucleotides 1453 to 2904). Gross deletion, nonsense, and
frameshift mutations were classified as truncating mutations, and
missense and splice mutations were analyzed separately.
Statistical Analyses
Time from birth to ESRD (i.e., renal death) was computed by the
product-limit (i.e., Kaplan-Meier) method of survival analysis. To
assess the differences in renal survival (i.e., freedom from ESRD)
between specific patient groups of interest, a two-sided log-rank test
was used. Additionally, time to ESRD plus death was analyzed as an
additional outcome measure. The effects of the covariates (i.e., gender
and hypertension) on renal survival were tested using the univariate
Cox proportional hazards model or the log-rank test for continuous or
categorical variables, respectively (29). Linear regression analysis
was also performed to assess the influence of the position of the PKD2
mutations on the age of onset of ESRD and CRF separately. The
running average of the age of onset of ESRD and CRF in Figure 2 was
based on the best fitting cubic spline function of the age versus
nucleotide relationship. For the linear regression and renal survival
analyses, the results based on ESRD alone or ESRD plus death were
not significantly different. Thus, only the results based on ESRD
alone will be presented because this outcome measure provides a
more accurate assignment of renal survival. All the analyses were
performed using the SPSS version 11.0.1 (SPSS, Chicago, IL) and
PRISM version 3.0 (GraphPad Software, Inc. San Diego, CA) statis-
tical packages.
Results
Clinical Characteristics of Study Patients
We analyzed the clinical and genetic data of 461 affected
individuals (44.2% male; 55.8% female) from 71 families in
Figure 2. Renal survival (i.e., absence of ESRD) analysis. The probability of renal survival differs significantly between female (n  221) than
male (n  174) patients with PKD2 mutations (2  27.9; P  0.00005 by log-rank test). On average, female patients developed ESRD 8 yr
later than male patients with PKD2 mutations.
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Table 1. The spectrum of PKD2 mutations in study families
Family Exon Nucleotide Sequence Change Predicted Protein Change
1g 1 to 15 PKD2del Gene deletion
2a 1 124ins52 Frameshift 423108X
3b 1 125–128delC Frameshift 433116X
4c 1 InsC231 Frameshift 78390X
5b 1 306–307delG Frameshift 1033116X
6d 1 534–538insC Frameshift 1803212X
7c 1 C556T R186X
8a 1 IVS11G3A Splicing defect
9e 2 InsC693 Frameshift 1943231X
10c 2 667 delG Frameshift 2223232X
11f 4 857 delC Frameshift 2863315X
12a, 13a 4 C916T R306X
14c 4 C958T R320X
15d 4 972–973insC Frameshift 3253340X
16g 4 G1066C A356P
17a 4 IVS42T3G Splicing defect
18a 4 IVS43del4 Splicing defect
19a, 20a 4 IVS413del4 Splicing defect
21a 5 T1158A T386X
22a, 23d 5 1194del2 Frameshift 3993407X
24e 5 C1213T Q405X
25d 5 T1240G W414G
26b, 27b, 28c, 29b 5 C1249T R417X
30a, 31a, 32g, 33g, 34g 5 IVS51G3A Splicing defect
35g, 36g 6 1335ins4 Frameshift 4463478X
37g 6 dup1369–1346 Frameshift 4573476X
38d 6 1362–1363delTT Frameshift 4553460X
39b, 40c 6 C1390T R464X
41d 6 1445delT Frameshift 4823513X
42b 6 1446–1149del4 Frameshift 4823513X
43a 7 C1609T Q537X
44h 7 C1663T Q555X
45h 7 1699del4T Frameshift 5673582X
46d 7 IVS7-3C3G Splicing defect
47c 8 C1753T Q585X
48a 8 T1894C C632R
49a 9 1998del4 Frameshift 6663672X
50c 10 2023–2024delAT Frameshift 6753681X
51h 11 2151delG Frameshift 7173735X
52b, 53c, 54g 11 2152–2159delA Frameshift 7203736X
55b, 56b, 57b 11 2152–2159insA Frameshift 7203724X
58a, 59e, 60e 11 C2224T R742X
61a 12 IVS12-7T3A Splicing defect
62c 13 C2419T R807X
63a 13 G2420A R807Q
64i 13 2436insT L813X
65c 13 G2509T E837X
66g 13 AG2511C Frameshift 8373843X
67g, 68g 14 C2533T R845X
69a, 70a, 71a 14 C2614T R872X
a Family described in this article for the first time.
b Family previously reported by Pei et al. (20).
c Family previously reported by Hateboer et al. (15).
d Family previously reported by Veldhuisen B et al. (18).
e Family previously reported by Demetriou et al. (22).
f Family previously reported by Aguiari et al. (21).
g Family previously reported by Torra et al. (24).
h Family previously reported by Viribay et al. (19).
i Family previously reported by Iglesias et al. (23).
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which the germline PKD2 mutations were characterized. Over-
all, 117 of these affected individuals (25.4%) had ESRD, 47
died without ESRD (10.2%), 65 (14.0%) had CRF, and 232
(50.3%) had neither CRF nor ESRD at the last follow-up.
Although ruptured intracranial arterial aneurysm was the pri-
mary cause of death in at least seven affected individuals who
died without ESRD, the cause of death was not available for
the remaining 40 patients. BP information was available in 103
of 182 individuals with either ESRD or CRF, and hypertension
was present in 68 (66%) of these 103 individuals. Figure 1
shows the frequency distribution of the study patents by their
age of onset of ESRD, CRF, and death. Typical of type 2
ADPKD, the mode of distribution of these events occurred at
a relatively late age (i.e., age range of 60 to 79 yr). However,
considerable renal disease variability (e.g., age range of onset
of ESRD: 40 to 88 yr) was also evident between individual
patients. In general, female patients had milder renal disease
than male patients (i.e., the mean age of onset of ESRD and
CRF was 76.0 [95% CI, 73.8 to 78.1] versus 68.1 [95% CI,
66.0 to 70.2] and 72.5 [95% CI, 70.1 to 74.9] versus 63.7 [95%
CI, 61.4 to 66.0] yr, respectively). The renal survival (i.e.,
absence of ESRD) curves also differed significantly between
the two gender groups (Figure 2).
Spectrum of PKD2 Mutations
Fifty different mutations from 71 families were included in
the current study (Table 1). These mutations spanned the entire
PKD2, with the exception of exons 3 and 15, for which no
mutations have been reported thus far. Among these 71 fami-
lies, 27 (38.0%) had nonsense mutations, 27 (38.0%) had
frameshift mutations, 12 (16.9%) had splice site mutations, 4
(5.6%) had missense mutations, and one (1.5%) had a complete
deletion of PKD2. The four missense mutations (A356P;
W414G; C632R; R807Q) included in this study all involved
nonconservative amino acid changes, segregated only in the
affected members of the same family and were not observed in
at least 100 normal chromosomes. Several mutations recurred
in apparently unrelated families. Of interest, a single nucleotide
deletion or insertion of a polyadenosine tract (2152–2159delA
and 2152–2159insA) on exon 11 accounted for frameshift
mutations in six families. Additionally, the same splice site
mutation in exon 5 (i.e. IVS51G3A) was responsible for the
mutation in three Spanish and two Canadian families. The
frequencies of various clinical events (i.e., ESRD, CRF, and
death) in the patients with different types of PKD2 mutations
are detailed in Table 2.
Genotype-Renal Function Correlation
We analyzed the correlation between the age of onset of
ESRD and the nucleotide position of the PKD2 mutation in the
study patients (upper panel of Figure 3). Linear regression
analysis showed a correlation coefficient (r) of 0.109 (r2 
0.012), and the slope of the regression line did not differ
significantly from zero (slope value: 0.001 [95% CI, 0.001 to
0.004]). Similarly, we analyzed the correlation between the age
of onset of CRF and the nucleotide position of the PKD2
mutation in the study patients (upper panel of Figure 3). Linear
regression analysis showed a correlation coefficient (r) of
0.036 (i.e., r2  0.001), and the slope did not differ signifi-
cantly from zero (slope value: 0.0004 [95% CI, 0.004 to
0.003]). These results remained unchanged when the correla-
tion was stratified by gender. At the last follow-up, 232 study
patients had not developed either CRF or ESRD and a plot of
their age by the position of the PKD2 mutations is shown in the
lower panel of Figure 3. Considerable renal disease variability
was noted among patients with the same mutations. For exam-
ple, five patients (i.e., boxed in the upper panel of Figure 3)
whose mutations clustered around the nucleotide position of
1000 to 1500 of the open reading frame of PKD2, had atypi-
cally severe renal disease (i.e., ESRD before 50 yr of age).
However, on close inspection they represented cases at one end
of the spectrum of disease severity among patients with the
same PKD2 mutations (Figure 4). In contrast, several patients,
who did not have CRF even after 70 yr of age (lower panel of
Figure 3), represented cases with exceptionally mild disease.
We also analyzed the renal survival of the study patients by
the types (i.e., missense, truncating, and splice site) as well as
location (i.e., 5' or nt 1–1452 versus 3' or nt 1453–2904) of
their PKD2 mutations (Table 3; Figure 5). We found that
neither the types (P  0.26 by log-rank test; upper panel) nor
the location (P  0.78 by log-rank test; lower panel) of the
PKD2 mutations influence the renal survival of our patients.
Gender was a significant determinant of renal survival; we
therefore also repeated the survival analyses using univariate
proportional-hazards models to include gender as a covariate.
In the gender-adjusted analysis, we found that patients with
splice site mutations appeared to have a more favorable renal
survival compared with patients with other mutation types (i.e.,











Patients with ESRD 5 52 9 10 41 117
Patients who died without ESRD 0 18 1 4 24 47
Patients with CRF 0 23 2 12 28 65
Patients without CRF or ESRD 6 76 14 19 117 232
Total 11 169 26 45 210 461
a ESRD, end-stage renal disease; CRF, chronic renal failure.
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P  0.046; Figure 6). On the other hand, the 5' and 3' location
of the PKD2 mutations did not influence renal survival. Hy-
pertension (i.e., presence or absence), included as a covariate in
univariate proportional-hazards models, did not change our
findings.
Discussion
In this study, we have examined the genotype-renal function
correlation in a large cohort of patients from families with
known PKD2 mutations. Consistent with the published litera-
ture (3,15), we found in our study patients a late age of onset
of ESRD (i.e., mean age of 72 yr) and a strong gender effect on
renal disease severity (i.e., P  0.00005 by log-rank test). The
mutations identified in the study families, spanning between
exons 1 and 14, also covered the entire spectrum of PKD2
mutations reported to date (25). Several of these mutations are
of particular interest (Table 1). For example, the four missense
mutations (A356P; W414G; C632R; R807Q) included in this
study all involved nonconservative amino acid changes, seg-
regated only in the affected members of the family, and were
Figure 3. Linear regression analysis of renal disease severity and nucleotide position of PKD2 mutations in the study patients. The slope of
the regression line for patients with ESRD (blue square) and CRF (red diamond) did not significantly differ from zero (upper panel).
Considerable disease variability was noted among patients with the same mutations. For example, five patients with four different PKD2
mutations (boxed in the upper panel) had atypically severe disease with ESRD before 50 yr of age. However, these patients represented
discordant cases among patients with the same PKD2 mutation (see Figure 4). In contrast, several patients (green triangles in lower panel), who
did not have CRF even after 70 yr of age, represented cases with exceptionally mild disease.
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not observed in the normal population. They are also predicted
to change within the mutant polycystin 2–specific amino acids
that are evolutionarily conserved between different organisms
(data not shown). However, structural-functional analyses have
not been performed on these mutations. Nonetheless, W414G,
by virtue of its location within the polycystin domain, may
disrupt the dimerization of polycystin 2 with itself and with
polycystin 1 (12,14). In contrast, C632R and R807Q, located in
the pore region and endoplasmic reticulum retention domain,
may disrupt the channel function of polycystin 2 (11,14). It is
also conceivable that some of these missense changes may in
fact result in aberrant splicing, as recently described in another
PKD2 mutation: nt A2657G (30). Of the recurring mutations,
two involving an insertion or deletion of a polyadenosine tract
(i.e., 2152–2159delA and 2152–2159insA) are of interest.
These mutations were observed in six apparently unrelated
families from different geographical regions, suggesting that
the polyadenosine tract (p(A)8: nt 2152–2159) on exon 11 is a
regional hot spot within PKD2 that predisposes to both germ-
line (Table 1) and somatic mutations (31), presumably by
“slipped strand mispairing” (20).
The location but not the types of PKD1 mutations has been
recently reported to influence renal disease severity in a large
cohort of patients with type 1 ADPKD (16). Specifically,
patients with mutations localized to the 5' half of PKD1 had an
earlier onset of ESRD compared with patients with mutations
localized to the 3' half of the gene (i.e., median age of onset of
ESRD: 53 versus 56 yr, respectively; P  0.025). However,
Figure 4. Significant renal disease variability among patients with the same PKD2 mutations. Five patients (see Figure 3), whose mutations
clustered around the nucleotide position of 1000 to 1500 of the open reading frame of PKD2, had atypically severe renal disease. However,
they represented discordant cases among patients with the same PKD2 mutations. One or more older patients with the same mutations had mild
renal disease typical of type 2 ADPKD (square denotes ESRD; diamond denotes CRF).
Table 3. Time to ESRD or ESRD plus death by gender and mutation locationa
Mean Time (yr) Median Time (yr)
ESRD
overall 72.3 (70.7 to 73.9) 72.0 (70.7 to 73.3)
male 68.1 (66.0 to 70.2) 68.0 (65.4 to 70.6)
female 76.0 (73.8 to 78.1) 77.0 (71.9 to 82.1)
mutations 5 to nt 1452 72.2 (69.8 to 74.6) 71.0 (68.7 to 73.3)
mutations 3 to nt 1453 72.5 (70.3 to 74.6) 72.0 (69.2 to 74.8)
ESRD  death
overall 70.7 (69.3 to 72.1) 71.0 (69.9 to 72.1)
male 67.3 (65.5 to 69.1) 67.4 (66.0 to 68.8)
female 73.9 (71.9 to 75.8) 74.0 (70.3 to 77.7)
mutations 5 to nt 1452 70.0 (68.0 to 72.0) 70.0 (68.5 to 71.5)
mutations 3 to nt 1453 71.5 (69.6 to 73.5) 72.0 (69.8 to 74.2)
a Mean and median time (95% confidence interval) from Kaplan-Meier survival analyses.
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this effect is weak compared with the locus effect between
PKD1 and PKD2 mutations (15). Given that most PKD1
mutations are predicted to be protein-truncating, these data
have led to the suggestion that mutations in the 3'-end of this
gene may result in partially functional gene products (16). In
the current study, we were unable to detect a position effect in
our patients by either linear regression or renal survival anal-
yses. With a large patient sample size and adjustment for the
gender effect, we believe that our analyses are robust. Most
PKD2 mutations are also predicted to truncate the C'-terminus
of polycystin 2; it therefore appears that the loss of the coil-coil
interaction region with polycystin 1 (i.e., the most distal C'-
terminal functional domain so far identified) may be sufficient
to completely inactivate the mutant protein (11,12,14). Recent
human (31–33) and knockout mouse (34,35) studies have
suggested that a common mechanism for individual cyst for-
mation in ADPKD results from the inactivation of PKD1 or
PKD2 within an epithelial cell, through germline and somatic
mutations. Our data are consistent with this classical two-hit
model of cystogenesis in ADPKD and suggest that most PKD2
mutations are completely inactivating.
In contrast to the lack of correlation between the mutation
types and renal disease severity seen in type 1 ADPKD (16),
we found that our patients with PKD2 splice site mutations
appeared to have milder renal disease compared with patients
with other mutation types (P  0.046 by log-rank test; Figure
6). Among the families with the splice site mutations, one
family (family 61; IVS12–7T3A; Table 1) had notably mild
disease, with five elderly affected individuals developing only
CRF at age 70, 71, 79, 80, and 83 yr, respectively. It is
conceivable that certain splice site mutations may be “leaky,”
so that low levels of a normal protein product can still be
Figure 5. Renal survival (i.e., absence of ESRD) of the study patients by the types (i.e., missense, truncating, or splice site mutations) and
location (i.e., 5' half versus 3' half) of their PKD2 mutations. Neither the types (P  0.26 by log-rank test; upper panel) nor the location (P
 0.78 by log-rank test; lower panel) of the mutations appeared to influence the renal survival of the study patients.
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generated by the mutant allele. Should this be the case, a
threshold model for polycystin 2 within individual epithelial
cells of patients with such mutations may provide an additional
mechanism for the cystogenic process. Under this model, in-
dividual cells with low levels of a functional polycystin may be
triggered into a cystogenic pathway by local stresses and other
stochastic factors (36,37). Alternatively, it is possible that the
above observation may be spurious, given the borderline sta-
tistical association and the presence of a significant “modifier
effect” (see below).
The most definitive conclusion of our study is that signifi-
cant renal disease variability exists among the patients with the
same PKD2 mutations (Figures 1 and 3). Within individual
families, we have observed both elderly patients with very mild
renal disease and younger patients with ESRD (Figure 4). This
is consistent with the finding of significant renal disease vari-
ability within families with PKD1-linkage (38) and among
patients with the same PKD1 mutations (16). Taken together,
these data suggest the existence of a modifier effect for AD-
PKD (17,38,39). Recent studies have shown that the pheno-
typic variability of a number of Mendelian disorders is in fact
complex because of the existence and interaction of genetic
and environmental modifiers (40). Some recent examples in-
clude cystic fibrosis (41) and Hirschsprung disease (42), in
which one or more modifier loci/genes have been implicated
from both animal models and patients. Indeed, several popu-
lation-based studies have recently examined the polymorphic
variants of the angiotensin-converting enzyme (ACE) (16,43–
46) and endothelial nitric oxide synthase (eNOS) (47,48) genes
as modifiers of renal disease progression in ADPKD. However,
these studies are limited by their research study design and
small patient sample size, and they have produced conflicting
results. Future studies using a family-based research design
(49) and properly-powered patient sample size will be required
to dissect the individual components of this modifier effect.
The identification of specific genetic and environmental mod-
ifiers will have important relevance for individual patient prog-
nostication and mechanism-based therapy in ADPKD.
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